Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in NMOSD with Primary Sjögren's Syndrome
ChiCTR2500111123Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) and primary Sjögren's syndrome (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Relapse after enrollment. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)primary Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2500111123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111123.